TAK 659

Drug Profile

TAK 659

Alternative Names: TAK-659

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Millennium
  • Developer Takeda Oncology
  • Class Antineoplastics
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Breast cancer; Gastric cancer; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 24 Apr 2017 Millennium Pharmaceuticals plans a phase II trial for Diffuse large B-cell lymphoma (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in France, Italy, Spain, United Kingdom and USA (NCT03123393)
  • 01 Mar 2017 Millenium Pharmaceuticals terminates a phase I trial due to business decision and no safety or efficacy concerns in Solid tumours, gastric cancer and oesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, USA (PO) (NCT02551055)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top